Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
High Confidence RCTPrimary source: [Open]
Linked compounds: semaglutide
Outcomes summary
Cardiovascular outcomes trial in type 2 diabetes comparing semaglutide to placebo; designed to assess cardiovascular safety and major adverse cardiovascular events.
Limitations
Population and background therapies reflect the trial setting; endpoints and follow-up duration constrain inference about long-term effects.
Notes
Primary source: PMID 27633186 (see PubMed link on this page).